PURPOSE: To compare three equations developed to predict VO2 among patients diagnosed with one of two chronic diseases: essential hypertension (HTN), and fibromyalgia (FM).
The GP documented chronic diseases (essential hypertension, type 2 diabetes, chronic ischemic heart disease, heart failure, peripheral arterial disease, COPD, chronic kidney disease, spinal osteochondrosis, osteoarthritis of the hip, osteoarthritis of the knee, and osteoporosis with or without pathological fracture).
There are several major categories of hypertensive disorders, including gestational hypertension or pregnancy-induced hypertension (hypertension without proteinuria); pre-eclampsia (hypertension with proteinuria); chronic or essential hypertension (pre-existing hypertension); and chronic hypertension with superimposed pre-eclampsia [ 29].
These chronic ailments, essential hypertension, insulin resistance, congestion, diuretic resistance and cardiorenal disorders, have a multiplicity of underlying etiologies, yet their shared link with elevated central sympathetic drive identifies a common therapeutic target [ 3– 5].
Furthermore, compared to respiratory specific instruments, a great advantage of this questionnaire is that, alike other generic preference-based instruments, it allows simultaneous cost-utility comparisons between different treatment interventions in COPD and even between other chronic conditions essential in public health care with limited resources.
Understanding risk factors that initiate or accelerate chronic diseases is essential for developing high impact prevention and detection strategies.
This study aimed to compare the effects of two long-acting dihydropyridine calcium channel blockers (CCBs) with different pharmacologic properties, lercanidipine and nifedipine Gastro-Intestinal Therapeutic System (GITS), in the chronic treatment of essential hypertension.
The consequences and adaptive responses of acute or chronic inhibition of essential enzymes such as FASN are not fully understood.
Chronic shortages of essential drugs continue to compromise an already exhausted health system.
Therefore, development of a vaccine to prevent acute or chronic infection is essential.
